Avicanna Inc.

AVCN.TO has a debt-free capital structure, as evidenced by a debt-to-equity ratio of 0.0, indicating no long-term debt obligations. However, the company's liquidity position is weak, with a current ratio of 0.86, suggesting that its current liabilities exceed its current assets. The company reported negative operating and free cash flows of -1,181,240 and -2,272,010 respectively, indicating ongoing cash burn.

Profitability metrics are negative, with a return on equity of -1.0002 and a return on assets of -0.1339, both significantly below the industry median for biotechnology and medical research firms. The company reported a net loss of -2,844,220 and an operating loss of -2,782,360, reflecting poor operational performance.

The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification in the provided data. This lack of diversification increases exposure to market-specific risks.

Growth trajectory appears negative, with no disclosed revenue growth in the most recent period. The company's operating cash flow and free cash flow are both negative, indicating a lack of internal funding for expansion or R&D.

Risk factors include low liquidity and the absence of long-term debt, which may limit the company's ability to fund operations or pursue growth opportunities. The risk assessment indicates low dilution potential, with no immediate filing-based flags detected.

Recent events include the continued reporting of operating losses and negative cash flows, with no significant capital expenditures or R&D investments disclosed in the latest financial data.